Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP503052.RAgbF1IlRV8eho3_UwXYbxSJiAgYIiEqckX2I1-deET4k130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP503052.RAgbF1IlRV8eho3_UwXYbxSJiAgYIiEqckX2I1-deET4k130_assertion type Assertion NP503052.RAgbF1IlRV8eho3_UwXYbxSJiAgYIiEqckX2I1-deET4k130_head.
- NP503052.RAgbF1IlRV8eho3_UwXYbxSJiAgYIiEqckX2I1-deET4k130_assertion description "[In hemoglobinopathies, treatment with demethylating agents leads to reactivation of fetal HbF (the gamma-globin gene locus also possibly being another target for reactivation in MDS), and thus, HbF may potentially act as surrogate marker for activity of decitabine.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP503052.RAgbF1IlRV8eho3_UwXYbxSJiAgYIiEqckX2I1-deET4k130_provenance.
- NP503052.RAgbF1IlRV8eho3_UwXYbxSJiAgYIiEqckX2I1-deET4k130_assertion evidence source_evidence_literature NP503052.RAgbF1IlRV8eho3_UwXYbxSJiAgYIiEqckX2I1-deET4k130_provenance.
- NP503052.RAgbF1IlRV8eho3_UwXYbxSJiAgYIiEqckX2I1-deET4k130_assertion SIO_000772 16292549 NP503052.RAgbF1IlRV8eho3_UwXYbxSJiAgYIiEqckX2I1-deET4k130_provenance.
- NP503052.RAgbF1IlRV8eho3_UwXYbxSJiAgYIiEqckX2I1-deET4k130_assertion wasDerivedFrom befree-20140225 NP503052.RAgbF1IlRV8eho3_UwXYbxSJiAgYIiEqckX2I1-deET4k130_provenance.
- NP503052.RAgbF1IlRV8eho3_UwXYbxSJiAgYIiEqckX2I1-deET4k130_assertion wasGeneratedBy ECO_0000203 NP503052.RAgbF1IlRV8eho3_UwXYbxSJiAgYIiEqckX2I1-deET4k130_provenance.